Humana (NYSE:HUM) PT Lowered to $337.00 at Morgan Stanley

Humana (NYSE:HUM) had its price target decreased by Morgan Stanley from $342.00 to $337.00 in a report released on Thursday, September 26th, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the insurance provider’s stock.

Other equities analysts also recently issued reports about the stock. ValuEngine downgraded shares of Humana from a hold rating to a sell rating in a report on Wednesday, September 11th. UBS Group raised their target price on shares of Humana from $266.00 to $317.00 and gave the company a neutral rating in a report on Thursday, August 1st. JPMorgan Chase & Co. raised their target price on shares of Humana from $288.00 to $322.00 and gave the company an overweight rating in a report on Thursday, August 1st. Piper Jaffray Companies raised their target price on shares of Humana from $315.00 to $341.00 and gave the company an overweight rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald upgraded shares of Humana from a neutral rating to an overweight rating and lifted their price target for the stock from $300.00 to $345.00 in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $334.21.

Shares of HUM stock traded up $5.11 during mid-day trading on Thursday, hitting $266.26. The stock had a trading volume of 1,248,164 shares, compared to its average volume of 1,050,785. Humana has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The firm has a market cap of $34.29 billion, a PE ratio of 18.30, a PEG ratio of 1.09 and a beta of 0.83. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. The company’s 50-day simple moving average is $271.85 and its 200-day simple moving average is $266.92.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The firm had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. During the same quarter last year, the business earned $3.96 earnings per share. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. On average, analysts expect that Humana will post 17.67 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.20 dividend on an annualized basis and a yield of 0.83%. Humana’s payout ratio is 15.12%.

In other Humana news, insider Brian P. Leclaire sold 7,239 shares of Humana stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the transaction, the insider now directly owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The sale was disclosed in a filing with the SEC, which is available at this link. 0.54% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the business. Whittier Trust Co. acquired a new position in shares of Humana during the second quarter worth $27,000. Next Capital Management LLC acquired a new position in shares of Humana during the second quarter worth $27,000. Advantage Investment Management LLC lifted its position in shares of Humana by 287.1% during the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 89 shares in the last quarter. Coastal Investment Advisors Inc. lifted its position in shares of Humana by 1,110.0% during the second quarter. Coastal Investment Advisors Inc. now owns 121 shares of the insurance provider’s stock worth $33,000 after purchasing an additional 111 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Humana during the second quarter worth $36,000. 92.77% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: What is Liquidity?

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.